News

Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
Top news of the day from across the health care landscape.
Each member of the specialty pharmacy care team is an essential component in influencing and ensuring positive outcomes of therapy.
Top news of the day from across the health care landscape.
Official with the FDA today granted accelerated approval to erdafitinib (Balversa, Janssen) for adult patients with locally advanced or metastatic bladder cancer.
The expanded first-line indication makes pembrolizumab (Keytruda) monotherapy an option for more patients with non-small cell lung cancer.
Top news of the week from Specialty Pharmacy Times.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$